Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.
- The Industry’s Positive Outlook For ADCs In 2024
- The Good And Bad Of Copromotion
- “Ruthless” Resourcing Rules For CEOs
- Understanding And Navigating Diverse Regulatory Environments
- No Playbook For Leqembi: Eisai’s Long Game In Alzheimer’s Disease
- In The UK, Location Is Key To Survival For Life Sciences Startups
- How AI Is Helping Drug Developers Help Rare Disease Patients
- 1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin.
COMPANIES TO WATCH
Companies To Watch: Antiva Biosciences
Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.
A novel small molecule developer aims to shake up the solid tumor treatment landscape.
Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.
Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.
WHERE ARE THEY NOW
Where Are They Now? Ono Pharmaceuticals
Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
Where Are They Now? Roivant
"Where Are They Now?" looks back, and forward, at companies and executives previously covered in Life Science Leader magazine.
Where Are They Now? Karuna Therapeutics
A new series from Life Science Leader looks backward, and forward, at the biopharmaceutical companies that have previously appeared in the pages of Life Science Leader magazine.